The stock market stallions
Ocugen Inc (NASDAQ: OCGN) is a US based bio-pharma which has focused on developing a cure for blindness disease. However, the company has since shifted its efforts to develop a COVID-19 vaccine with partner Bharat Biotech. Ocugen’s CEO Shankar Musunuri has made it clear the company strategises to disrupt the current COVID-19 vaccine market with Covaxin.…
Clover Health Investments Corp (NASDAQ: CLOV) has struggled over the past month, declining to 52 week lows of $6.31 a share (a 36.9% decline from the PIPE offering price). Despite the decline, Clover is the fastest growing Medicare Advantage insurer in the United States.…
Novavax, Inc.(NASDAQ: NVAX) has seen an incredible year in stock price growth, increasing 307% over the past 12 months. The companies COVID-19 vaccine saw the market rally behind NVAX, posting a 52 week high in February of $331.68. The company announced yesterday that their COVID-19 vaccine NVX-CoV2373 demonstrated 100% protection against moderate and severe disease and a 90.4% efficacy overall in the Phase 3 trial.…
Vaxart Inc (NASDAQ: VXRT) stock has seen a recent spike in investor confidence, gaining 23.81% over the past week. Vaxart has developed an oral vaccine for COVID-19 which has vastly differentiated itself from the competition. A recent study by Quadrant Strategies has shown that one third of people refusing to be vaccinated for COVID-19, would take an oral vaccine as an alternative to an injection.…
Longterm shareholders of Biogen (NASDAQ:BIIB) rejoice today after the company received accelerated approval from the FDA for their Alzheimer’s treatment ADUHELM™. The approval marks a historic day as ADUHELM becomes the first treatment to receive approval that addresses an underlying pathology of the disease.…
Soaring Eagle Acquisition Corp. (NASDAQ:SRNG) is set to merge with bio tech company Ginkgo Bioworks in a $15 Billion deal. The mammoth deal is expected to provide the biotech company $2.5 Billion in primary cash proceeds to fund future growth within multiple industries.…
BioNano Genomics Inc (NASDAQ: BNGO) has had a remarkable year of trading, gaining over 979% over the past two months. The company operates in the analytical instruments field, in particular cytogenomics. Simply put, this is the detection of genetic disorders by analyzing the variances in chromosomes.…
Vaxart Inc (NASDAQ: VXRT) has seen a remarkable year on Wallstreet after investors rallied behind its experimental COVID-19 vaccine. VXRT stock has gained some serious ground over the past year, surging over 1,559% YTD. Unlike other COVID-19 vaccine candidates, the vaccine is administered orally and can be stored at room temperature.…
Sorrento Therapeutics Inc (NASDAQ: SRNE) has recaptured the attention of investors as analysts remain confident in the companies 12 month outlook. The stock has performed well as of late, posting a 29% gain over the past month of trading. Furthermore, the average 12 month price target amongst Wallstreet analysts is $29.67 a share.…
Social Capital Hedosophia (NYSE: IPOC) are set to close in on their merger with Clover Health in early 2021. Evidently, this has caused a strong upswing in investor momentum in IPOC’s trading price. IPOC has gained 33% over the past week of trading and 66% for the month of December.…
The past two weeks have seen a large shift in investor sentiment towards these two key COVID vaccine pioneers. Moderna Inc (NASDAQ: MRNA) and Novavax, Inc. (NASDAQ: NVAX) have seen a recent surge in the share price. The companies saw an increase of 26.52% (NVAX) and 38.26% (MRNA) respectively over the past week of trading.…
iBio inc. (NYSE:IBIO) rose to popularity amongst the investor community as they announced their intentions to develop a COVID-19 vaccine. The stock is currently trading 586% higher since the beginning of 2020. However since July, iBio stock has been on a downward slope which has since found a new equilibrium at $2.…
Sorrento Therapeutics (NASDAQ: SRNE) was lacking direction as short-sellers brought down the stock after most positive announcements. However, the green light from the FDA allows the bulls to lay down the trackwork. The clear path is promising, but the volatility is making it difficult for investors to enter.…
CVS Health (NASDAQ: CVS) stock has been going on a rollercoaster ride in 2020 so far. The start of the year was promising as the healthcare giant hit 52-week highs. Unfortunately, COVID-19 sent CVS spiraling down. Investors are currently unsure what is in store for CVS come 2021 and beyond.…
Will Teva stock recover from the recent bloodbath? It is the big question institutions and retail investors are asking. On one end, investors believe the lawsuit and stagnating financials will cripple Teva. Conversely, the bullish hedge funds argue that Teva holds value in the long-term.…
Sorrento Therapeutics (NASDAQ: SRNE) is putting on a volatility show this week. The bulls were leading the charge at the start of the week but took a big rest on Wednesday, which saw SRNE pullback by 12%. All bullish hope seemed lost.…
Inovio (NASDAQ:INO) is set to open 10% higher this morning after the promising address by CEO & President Dr. Joseph Kim on the H.C Wainwright 22nd Annual Investment Conference. Dr. Kim advised that the initiation of Phase 2 trials for their COVID-19 vaccine INO-4800 is on track to commence later this month.…
Biomerica (NASDAQ:BMRA) is set to release Q2 earnings this Friday, with experts forecasting an expected EPS of -$0.05. This would mark a 37% improvement for Q2 Earnings Year on Year. The medical diagnostic manufacturer has thrived on the opportunity this year to develop a viable COVID-19 test.…
Fluidigm Corporation (NASDAQ: FLDM) just became a bull-market magnet as its COVID-19 saliva kit received FDA approval. Optimism is high in pre-market trading as some bullish investors believe this is news to send FLDM soaring. However, the bears are screaming that a pump and dump is coming at the bell.…
Johnson & Johnson announced this morning that they have entered a “definitive agreement” to acquire Momenta Pharmaceuticals at $52.50 per share. The acquisition has been confirmed as an all-cash transaction, which has been approved “unanimously” by the Board of Directors from both J&J and Momenta.…